ProGRP as early predictive marker of non-small-cell lung cancer to small-cell lung cancer transformation after EGFR-TKI treatment.

Abstract

We report a case of non-small-cell lung cancer (NSCLC) to small-cell lung cancer (SCLC) transformation after epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment. The patient was a man who diagnosed with EGFR-mutant advanced NSCLC. After he was introduced afatinib, his tumor had been reduced by the treatment. However, plasma pro-gastrin-releasing peptide (ProGRP) became higher with disease progression, and SCLC was detected at the second biopsy. It is suggested that elevation of plasma ProGRP level before EGFR-TKI therapy is useful for predicting EGFR-mutant NSCLC to SCLC transformation.

• Authors: Yasuhiro Kato, Yosuke Tanaka, Mitsunori Hino, Akihiko Gemma
• Journal: Respiratory medicine case reports (Respir Med Case Rep) Vol. 27 Pg. 100837 ( 2019) ISSN: 2213-0071 [Print] England
• PMID: 31016132 (Publication Type: Case Reports)